SPLUNC1 as a biomarker of pulmonary exacerbations in children with cystic fibrosis

Cystic fibrosis (CF) is an autosomal recessive multiorgan disease that in the lung leads to impaired muco-ciliary clearance, chronic inflammation as well as acute and chronic bacterial infections, resulting in progressive loss of lung function [1,2]. Acute CF pulmonary exacerbations (PEx) usually are treated with anti-infectives; oral antibiotics for mild events and intravenous (IV) antibiotics for severe PEx [3,4]. However, while there is currently no universally accepted definition of severe PEx a [5,6], PEx episodes in children with CF treated with oral antibiotics are often not associated with significant spirometry changes [7].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Original Article Source Type: research